The presence of dendritic cells, antigen-presenting cells that link innate and adaptive immunity, is necessary to generate and maintain the production of antiphospholipid antibodies in response to exposed intracellular phospholipids on the outer surface of apoptotic cells. In turn, antiphospholipid antibodies enhance dendritic cell-induced inflammatory and proatherogenic responses in a number o...

The antiphospholipid syndrome (APS) is defined by the development of venous and/or arterial thromboses, often multiple, and pregnancy morbidity (mainly, recurrent fetal losses), in the presence of antiphospholipid antibodies (aPL). Some estimates indicate that the incidence of the APS is around 5 new cases per 100,000 persons per year and the prevalence around 40-50 cases per 100,000 persons. T...

The concept of antiphospholipid syndrome (APS) has been established (1). It is well-known that one of the clinical features in APSis arterial or venous thrombosis, and that the specificity of so-called antiphospholipid antibodies have diversity against their epitopes, as so-called antiphospholipid antibodies react to phospholipids as well as plasma proteins such as p2-glycoprotein I and prothro...

ISSN 1758-4272 10.2217/IJR.13.70 © 2014 Future Medicine Ltd Int. J. Clin. Rheumatol. (2014) 9(1), 1–3 “A high index of suspicion in order to make an early diagnosis, as well as aggressive therapy, are vital for the survival of catastrophic antiphospholipid syndrome patients. However, in a ‘real-world’ setting, even if catastrophic antiphospholipid syndrome is considered in the differential diag...

We present a 12-year-old girl with systemic lupus erythematosus and associated antiphospholipid syndrome who developed an unusual manifestation of purpura fulminans in an accelerated fashion. The patient improved after prompt treatment with anticoagulants, aggressive immunosuppressive drugs and plasmapheresis. This is the first pediatric case of purpura fulminans due to secondary antiphospholip...

Cutaneous involvement in primary and secondary antiphospholipid syndrome often is a therapeutical dilemma. Here we describe a case of widespread cutaneous necrosis due to thrombosis of the microvasculature, and cutaneous vasculitis in secondary antiphospholipid syndrome in a patient with systemic lupus erythematosus. Autologous skin transplantation was able to cover the skin defects but was onl...

We report here, we believe for the first time, the primary antiphospholipid syndrome, presenting with fever, meningismus and skin rash. Serology was positive for antiphospholipid antibodies but negative for antinuclear factor. Such presentations, once meningitis has been excluded, should be screened for antiphospholipid antibodies. If serology proves to be positive, anticoagulation for life sho...

It is nowwell knownthat symptomssuch as arterial and venous thrombosis, recurrent fetal loss, central nervous system involvement and thrombocytopenia in patients with systemic lupus erythematosus (SLE) are associated with the presence of antiphospholipid antibodies. In addition, antiphospholipid antibodies can be found in patients with no other apparent autoimmune diseases and maycause cerebral...

The aim of the research was to show our diagnostic and therapeutic experience with antiphospholipid syndrome (APS) in pregnant women. 36 pregnant women suspect on APS were included in the study: 32 with primary antiphospholipd syndrome (PAPS) and 4 with secondary antiphospholipid syndrome (SAPS). All pregnant women received low-molecular-weight-heparin (LMWH) and low dose aspirin (LDA) therapy....

Purpose We present a patient with systemic lupus erythematosus with significant vaso-occlusive retinal findings mimicking antiphospholipid antibody syndrome, who developed Kikuchi-Fujimoto disease. Observations Our patient was initially diagnosed with systemic lupus erythematosus with antiphospholipid antibody syndrome given consistent serologic markers and profound retinal vascular ischemia....